

## Brief Genetics Report

# The Krüppel-Like Factor 11 (*KLF11*) Q62R Polymorphism Is Not Associated With Type 2 Diabetes in 8,676 People

Jose C. Florez,<sup>1,2,3,4</sup> Richa Saxena,<sup>1,4</sup> Wendy Winckler,<sup>5</sup> Noël P. Burt, <sup>4</sup> Peter Almgren,<sup>6</sup> Kristina Bengtsson Boström,<sup>7</sup> Tiinamaija Tuomi,<sup>8,9</sup> Daniel Gaudet,<sup>10</sup> Kristin G. Ardlie,<sup>11</sup> Mark J. Daly,<sup>2,4</sup> David Altshuler,<sup>1,2,3,4,12</sup> Joel N. Hirschhorn,<sup>4,12,13</sup> and Leif Groop<sup>6,8</sup>

**Krüppel-like factor 11 is a pancreatic transcription factor whose activity induces the insulin gene. A common glutamine-to-arginine change at codon 62 (Q62R) in its gene *KLF11* has been recently associated with type 2 diabetes in two independent samples. Q62R and two other rare missense variants (A347S and T220M) were also shown to affect the function of *KLF11* in vitro, and insulin levels were lower in carriers of the minor allele at Q62R. We therefore examined their impact on common type 2 diabetes in several family-based and case-control samples of northern-European ancestry, totaling 8,676 individuals. We did not detect the rare A347S and T220M variants in our samples. With respect to Q62R, despite >99% power to detect an association of the previously published magnitude, Q62R was not associated with type 2 diabetes (pooled odds ratio 0.97 [95% CI 0.88–1.08],  $P = 0.63$ ). In a subset of normoglycemic individuals, we did not observe significant differences in various insulin traits according to genotype at *KLF11* Q62R. We conclude that the *KLF11* A347S and T220M mutations do not contribute to increased risk of diabetes in European-derived populations and that the Q62R polymorphism has, at best, a minor effect on diabetes risk. *Diabetes* 55:3620–3624, 2006**

From the <sup>1</sup>Department of Molecular Biology and Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts; the <sup>2</sup>Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; the <sup>3</sup>Department of Medicine, Harvard Medical School, Boston, Massachusetts; the <sup>4</sup>Medical and Population Genetics Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts; the <sup>5</sup>Cancer Biology Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts; the <sup>6</sup>Department of Endocrinology, University Hospital MAS, Lund University, Malmö, Sweden; the <sup>7</sup>Department of Clinical Science, University Hospital MAS, Lund University, Malmö, Sweden; the <sup>8</sup>Department of Medicine, Helsinki University Central Hospital and Research Program for Molecular Medicine, University of Helsinki, Helsinki, Finland; the <sup>9</sup>Folkhälsan Genetic Institute, Folkhälsan Research Center, Helsinki, Finland; the <sup>10</sup>University of Montreal Community Genomic Center, Chicoutimi Hospital, Chicoutimi, Quebec, Canada; the <sup>11</sup>Genomics Collaborative Division, SeraCare LifeSciences, Cambridge, Massachusetts; the <sup>12</sup>Department of Genetics, Harvard Medical School, Boston, Massachusetts; and the <sup>13</sup>Divisions of Genetics and Endocrinology, Children's Hospital, Boston, Massachusetts.

Address correspondence and reprint requests to Jose C. Florez, Simches Research Building, CPZN 6820, Diabetes Unit/Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114. E-mail: jcflorez@partners.org.

Received for publication 26 June 2006 and accepted in revised form 21 August 2006.

J.N.H. and L.G. contributed equally to this work.

K.G.A. is currently affiliated with the Biological Samples Platform, Broad Institute of Harvard and Massachusetts Institute of Technology.

AUC, area under the curve; GCI, Genomics Collaborative; OGTT, oral glucose tolerance test; SNP, single nucleotide polymorphism.

DOI: 10.2337/db06-0867

© 2006 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**K**rüppel-like factor 11 (*KLF11*) encodes an SP1-like transcription factor that is induced by transforming growth factor- $\beta$  and regulates cell growth in the exocrine pancreas (1). Because mutations in other transcription factors that act during pancreatic  $\beta$ -cell development can cause monogenic forms of diabetes (2) and the transforming growth factor- $\beta$  signaling pathway also determines endocrine cell fate, Neve et al. (3) recently studied this gene for its impact on insulin secretion and putative association with type 2 diabetes. They first documented expression of *KLF11* in pancreatic  $\beta$ -cells and showed that activated *KLF11* bound and induced the insulin promoter under high-glucose conditions. Sequencing of *KLF11* in families enriched for early onset of type 2 diabetes uncovered two novel missense mutations (A347S and T220M), which segregated with diabetes in three pedigrees but were absent in other samples. Other sequencing efforts led to the identification of 19 common polymorphisms (minor allele frequency >5%), several of which were associated with type 2 diabetes in an initial case-control sample totaling 626 French individuals. Further genotyping in an additional case-control sample of 2,846 northern-European subjects replicated the association of the Q62R polymorphism (rs35927125) with type 2 diabetes (combined odds ratio [OR] 1.29 [95% CI 1.12–1.49],  $P = 0.0003$ , under an additive model, and 1.32 [1.13–1.54],  $P = 0.0005$ , under a dominant model). The authors went on to show that these missense variants impaired transcriptional activity of *KLF11* and that the presence of the R-allele correlated with lower levels of insulin expression in vitro and insulin secretion in vivo (3).

Replication is essential in genetic association studies (4). In type 2 diabetes, the associations of the *PPARG* P12A and *KCNJ11* E23K polymorphisms have been widely reproduced (5) and a similar level of robust statistical evidence has emerged for variants in the *TCF7L2* gene (6–13). Determining which of the many variants in the genome are reproducibly associated with type 2 diabetes is essential in understanding the physiology and genetic architecture of this complex phenotype and pursuing viable prognostic and therapeutic options. The availability of well-characterized large diabetes samples and high-throughput genotyping technologies has allowed investigators to systematically attempt to confirm such reports of association. We therefore examined the three aforemen-

TABLE 1  
Characteristics of patient samples

Population	<i>n</i> (male/female)	Age (years)	BMI (kg/m <sup>2</sup> )	Fasting plasma glucose (mmol/l)	HbA <sub>1c</sub> (%)* or plasma glucose at 2-h OGTT (mmol/l)†
Scandinavia trios					
Probands	168/153	39 ± 9	27 ± 5	7.2 ± 2.6	8.5 ± 2.9†
Parents	236/236				
Sibships					
Diabetes/severe IGT sib	280/329	65 ± 10	29 ± 5	9.3 ± 3.3	14.3 ± 5.6†
NGT sib	275/305	62 ± 10	26 ± 3	5.4 ± 0.4	6.0 ± 1.1†
Scandinavia case/control					
Diabetes/severe IGT	252/219	60 ± 10	28 ± 5	9.8 ± 3.4	15.0 ± 5.3†
NGT	254/217	60 ± 10	27 ± 4	6.2 ± 1.8	6.8 ± 2.8†
Sweden case/control					
Diabetes/severe IGT	267/247	66 ± 12	28 ± 4	9.6 ± 2.9	6.5 ± 1.5*
NGT	267/247	66 ± 12	28 ± 4	5.5 ± 0.7	ND
Canada case/control					
Diabetes	70/57	53 ± 8	29 ± 5	6.4 ± 1.8	12.8 ± 2.1†
NGT	70/57	52 ± 8	29 ± 4	5.1 ± 0.6	6.1 ± 1.1†
U.S. case/control					
Diabetes	644/582	63 ± 11	33 ± 7	9.8 ± 3.0	8.0 ± 3.1*
NGT	644/582	61 ± 10	27 ± 5	5.1 ± 0.9	ND
Poland case/control					
Diabetes	422/587	62 ± 10	30 ± 5	8.9 ± 4.0	7.9 ± 1.3*
NGT	422/587	59 ± 7	26 ± 4	4.8 ± 1.2	ND

Data are means ± SD. Plasma glucose was measured at baseline (fasting) and 2 h after an OGTT. Severe impaired glucose tolerance (IGT) was defined as an OGTT 2-h blood glucose ≥8.5 mmol/l but <10.0 mmol/l. ND, not determined; NGT, normal glucose tolerance.

tioned missense variants in *KLF11* for association with type 2 diabetes and/or insulin-related phenotypes in several well-powered case-control and family-based samples.

## RESEARCH DESIGN AND METHODS

The diabetes samples are presented in Table 1 and have been described previously (14,15). Briefly, Scandinavian samples from the Botnia Study (16) include 321 trios, 1,189 siblings discordant for type 2 diabetes, and a case-control sample totaling 942 subjects individually matched for age, BMI, and region of origin. In the Botnia Study, case subjects included individuals with type 2 diabetes or severe impaired glucose tolerance, defined as a 2-h blood glucose ≥8.5 mmol/l but <10.0 mmol/l during an oral glucose tolerance test (OGTT). In addition, we studied a case-control sample from Sweden totaling 1,028 subjects who were individually matched for sex, age, and BMI; an individually matched case-control sample totaling 254 subjects from the Saguenay Lac-St. Jean region in Quebec (Canada); and two case-control Caucasian diabetes samples obtained from Genomics Collaborative (GCI): one comprised of 1,226 case and 1,226 control subjects from the U.S. and one comprised of 1,009 case and 1,009 control subjects from Poland, both matched for age, sex, and grandparental country of origin. These samples have been validated by the replication of the three most widely reproduced associations in type 2 diabetes, *PPARG* P12A (14), *KCNJ11* E23K (17,18), and *TCF7L2* (12). **Genotyping.** Genotyping was performed by allele-specific primer extension of multiplex products with detection by MALDI-TOF on the Sequenom platform (19,20). Average genotyping success was 96.2%, and there were no discrepancies in comparisons of 1,873 duplicate genotypes, indicating a low error rate. Genotype counts for the various samples tested in this study are shown in Table 2.

**Statistical analysis.** Power calculations were performed using the program of Purcell et al. (21) (<http://pngu.mgh.harvard.edu/~purcell/gpc/>). To examine the association of single nucleotide polymorphisms (SNPs) and haplotypes with type 2 diabetes, we used simple  $\chi^2$  analysis in the case-control samples, the transmission disequilibrium test (22) in the diabetic trios, and the discordant allele test (23) in the sib pairs. Results from the various samples were combined by Mantel-Haenszel meta-analysis of the OR (24); all *P* values are two tailed. Homogeneity of ORs among study samples was tested using an asymptotic Breslow-Day statistic (25).

**Quantitative trait comparisons.** Plasma glucose was measured by a glucose oxidase method on a Beckman Glucose analyzer (Beckman Instruments, Fullerton, CA). Insulin was measured by radioimmunoassay. A 75-g OGTT was performed in a subset of the control Scandinavian subjects (*n* =

791, 382 female). The insulinogenic index was calculated as [(insulin at 30 min) – (insulin at 0 min)]/(glucose at 30 min) – (glucose at 0 min)]; insulin area under the curve (AUC) was calculated by the trapezoidal method. BMI, the insulinogenic index, insulin AUC, and insulin levels at 0, 60, and 120 min were log transformed to improve normality and compared by ANOVA across the three genotypic groups and by *t* test between Q/Q homozygotes and Q/R heterozygotes.

## RESULTS

The two rare variants (A347S and T220M) were monomorphic in our samples. Assuming a type 2 diabetes prevalence of 8%, a minor allele frequency for Q62R of 10%, and the published OR of 1.29, our power calculations demonstrated that our combined sample of 3,347 case-control pairs, 321 trios, and 1,189 discordant sibs had >99% power to detect an association with type 2 diabetes under additive or dominant models; this power would obviously be reduced if the initial association was an overestimate of the true effect due to the “winner’s curse” (26).

Genotype counts, ORs, *P* values, and a meta-analysis of the association studies for the common Q62R polymorphism are presented in Table 2. No heterogeneity was detected among subsamples. We observed no significant association of Q62R with type 2 diabetes (pooled OR 0.97 [95% CI 0.88–1.08], *P* = 0.63).

Because our Scandinavian case-control samples were matched for BMI, it is possible that overmatching may have prevented us from detecting a true effect on risk of type 2 diabetes, if this effect was mediated through BMI. We therefore assessed whether BMI was associated with Q62R in the Scandinavian normoglycemic subjects; no significant differences in BMI were detected across genotypic groups at *KLF11* Q62R.

Since *KLF11* has been postulated to affect insulin gene expression in vitro and insulin levels in vivo (3), we attempted to replicate these findings in a subset of 791

TABLE 2  
Genotype counts for the *KLF11* Q62R polymorphism in the various subsamples

Family based	Transmitted		Untransmitted		MAF	OR (95% CI)	P value
Trios	27		36		0.09	0.75 (0.46–1.23)	0.26
	Excess in affected		Excess in unaffected				
Discordant sibs	23		25		0.09	0.92 (0.52–1.62)	0.77
Case/control	G/G (R/R)	A/G (Q/R)	A/A (Q/Q)				
Scandinavia							
Case subjects	7	74	388		0.09		
Control subjects	8	66	394		0.09	1.08 (0.79–1.48)	0.64
Sweden							
Case subjects	7	88	409		0.10		
Control subjects	3	90	410		0.10	1.07 (0.80–1.43)	0.66
Canada							
Case subjects	2	23	86		0.12		
Control subjects	4	22	83		0.14	0.87 (0.50–1.51)	0.62
GCI U.S.							
Case subjects	16	253	938		0.12		
Control subjects	15	263	920		0.12	0.96 (0.81–1.14)	0.65
GCI Poland							
Case subjects	18	175	807		0.11		
Control subjects	11	193	793		0.11	0.98 (0.80–1.19)	0.81
<b>Overall</b>						0.97 (0.88–1.08)	0.63

The transmission disequilibrium test and the discordant allele test were performed in the Scandinavian trios and the discordant sibpairs, respectively. ORs were calculated for the minor allele (G, coding for arginine) versus the major allele (A, coding for glutamine) and pooled by Mantel-Haenszel analysis. MAF, minor allele frequency.

Scandinavian normoglycemic individuals for whom we had OGTT data. We found no significant differences across genotypic groups in the insulinogenic index, insulin AUC, or absolute insulin levels at 0, 60, or 120 min during an OGTT (Table 3).

To test our expectation that the haplotype structure of the French samples in the study by Neve et al. (3), and that of other European populations, is comparable at this locus, we also genotyped rs4444493 (SNP 17 in ref. 3, located 6.7 kb downstream of Q62R) in the HapMap CEU plate and in a subset of our samples. As previously observed in the French population, linkage disequilibrium between the two SNPs is strong ( $D' = 1.0/r^2 = 1.0$  in the HapMap CEU sample, and 1.0/0.95, 0.98/0.94, and 0.99/0.97, respectively, in the Scandinavian, U.S., and Polish samples), reflecting their similar ancestral origin.

## DISCUSSION

We set out to replicate the association of missense variants in the *KLF11* gene with type 2 diabetes and to confirm

TABLE 3  
Quantitative traits in 791 control subjects according to genotype at Q62R

Trait	R/R	Q/R	Q/Q	P ANOVA	P (t test) Q/R vs. Q/Q
<i>n</i>	19	111	661		
BMI (kg/m <sup>2</sup> )	25.8 ± 3.2	26.5 ± 3.5	26.4 ± 3.8	0.81	0.80
Insulin <sub>0</sub> (mU/l)	8.2 ± 5.5	8.6 ± 4.5	8.1 ± 5.0	0.56	0.30
Insulin <sub>60</sub> (mU/l)	50.4 ± 27.4	68.0 ± 51.4	65.7 ± 43.1	0.37	0.77
Insulin <sub>120</sub> (mU/l)	35.7 ± 25.6	49.7 ± 40.6	44.2 ± 35.2	0.36	0.28
Insulinogenic index	22.2 ± 20.9	18.3 ± 14.0	22.0 ± 36.0	0.83	0.78
Insulin AUC (units/l)	4.4 ± 2.6	5.4 ± 3.8	5.1 ± 3.2	0.55	0.59

Data are mean ± SD.

Second, our analysis may have yielded false-negative results. While the power of a meta-analysis of seven smaller subsamples is not equivalent to a single association study of the same size, we note that no heterogeneity was detected among our subsamples and that the present design takes advantage of two family-based panels that are robust to population stratification. In addition, these same samples have been adequate to detect the most commonly reproduced genetic associations with type 2 diabetes (12,14,17,18). Nevertheless, if the true genotypic risk ratio is lower than the original estimate, we may have been underpowered to detect it. We note that our 95% CI does not overlap with the one reported by Neve et al. (3) (see above), suggesting that it is highly unlikely that the OR in our population lies within the interval estimate of the original report. In either case, it appears that even if Q62R does increase the risk of type 2 diabetes, its influence is quite modest.

Finally, the initial association signal may have arisen from another *KLF11* variant that was in linkage disequilibrium with Q62R in the original samples but not in ours. The similar haplotype structure of populations that share northern-European ancestry (27,28), the strong linkage disequilibrium between Q62R and rs4444493 in the French, Scandinavian, U.S., and Polish samples, and our failure to detect such an association in three different Caucasian samples also makes this explanation less likely. Upcoming high-density whole-genome association scans in large samples should be able to answer whether other common variants in *KLF11* might contribute to diabetes risk.

#### ACKNOWLEDGMENTS

J.C.F. is supported by the National Institutes of Health Research Career Award 1 K23 DK65978-03. T.T. is a Research Fellow at the Academy of Finland. D.A. is a Charles E. Culpeper Scholar of the Rockefeller Brothers Fund and a Burroughs Wellcome Fund Clinical Scholar in Translational Research. D.A., M.J.D., and J.N.H. are recipients of The Richard and Susan Smith Family Foundation/American Diabetes Association Pinnacle Program Project Award. L.G., T.T., and the Botnia Study are principally supported by the Sigrid Juselius Foundation, the Academy of Finland, the Finnish Diabetes Research Foundation, The Folkhalsan Research Foundation, the European Community (BM4-CT95-0662), the Swedish Medical Research Council, the J.D.F. Wallenberg Foundation, and the Novo Nordisk Foundation.

We thank the members of the Altshuler, Hirschhorn, Daly, and Groop labs for helpful discussions and the participants of the studied cohorts for the contribution of their DNA samples and phenotypic measurements.

#### REFERENCES

- Fernandez-Zapico ME, Mladek A, Ellenrieder V, Folch-Puy E, Miller L, Urrutia R: An mSin3A interaction domain links the transcriptional activity of *KLF11* with its role in growth regulation. *EMBO J* 22:4748–4758, 2003
- Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. *N Engl J Med* 345:971–980, 2001
- Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, Dina C, Hamid YH, Joly E, Vaillant E, Benmezroua Y, Durand E, Bakaher N, Delannoy V, Vaxillaire M, Cook T, Dallinga-Thie GM, Jansen H, Charles M-A, Clement K, Galan P, Hercberg S, Helbecque N, Charpentier G, Prentki M, Hansen T, Pedersen O, Urrutia R, Melloul D, Froguel P: Role of transcription factor *KLF11* and its diabetes-associated gene variants in pancreatic beta cell function. *Proc Natl Acad Sci U S A* 102:4807–4812, 2005
- Hattersley AT, McCarthy MI: What makes a good genetic association study? *Lancet* 366:1315–1323, 2005
- Barroso I: Genetics of type 2 diabetes. *Diabet Med* 22:517–535, 2005
- Grant SFA, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadóttir A, Styrkarsdóttir U, Magnusson KP, Walters GB, Palsdóttir E, Jonsdóttir T, Gudmundsdóttir T, Gylfason A, Saemundsdóttir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdóttir U, Gulcher JR, Kong A, Stefansson K: Variant of transcription factor 7-like 2 (*TCF7L2*) gene confers risk of type 2 diabetes. *Nat Genet* 38:320–323, 2006
- Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PIW, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D, the Diabetes Prevention Program: *TCF7L2* polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N Engl J Med* 355:241–250, 2006
- Groves CJ, Zeggini E, Minton J, Frayling TM, Weedon MN, Rayner NW, Hitman GA, Walker M, Wiltshire S, Hattersley AT, McCarthy MI: Association analysis of 6,736 U.K. subjects provides replication and confirms *TCF7L2* as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. *Diabetes* 55:2640–2644, 2006
- Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, van Dam RM, Hu FB: Variant of transcription factor 7-like 2 (*TCF7L2*) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. *Diabetes* 55:2645–2648, 2006
- Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N, Duren WL, Chines PS, Stringham HM, Erdos MR, Valle TT, Tuomilehto J, Bergman RN, Mohlke KL, Collins FS, Boehnke M: Association of transcription factor 7-like 2 (*TCF7L2*) variants with type 2 diabetes in a Finnish sample. *Diabetes* 55:2649–2653, 2006
- Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, Mitchell BD, Shuldiner AR: Polymorphisms in the transcription factor 7-like 2 (*TCF7L2*) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. *Diabetes* 55:2654–2659, 2006
- Saxena R, Gianniny L, Burt NP, Lyssenko V, Giuducci C, Sjogren M, Florez JC, Almgren P, Isomaa B, Orho-Melander M, Lindblad U, Daly MJ, Tuomi T, Hirschhorn JN, Ardlie KG, Groop LC, Altshuler D: Common single nucleotide polymorphisms in *TCF7L2* are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. *Diabetes* 55:2890–2895, 2006
- Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B, Charpentier G, Pattou F, Stetsyuk V, Scharfmann R, Staels B, Fruhbeck G, Froguel P: Transcription factor *TCF7L2* genetic study in the French population: expression in human  $\beta$ -cells and adipose tissue and strong association with type 2 diabetes. *Diabetes* 55:2903–2908, 2006
- Altshuler D, Hirschhorn JN, Klanenmark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPAR $\gamma$  Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet* 26:76–80, 2000
- Winckler W, Graham RR, de Bakker PIW, Sun M, Almgren P, Tuomi T, Gaudet D, Hudson TJ, Ardlie KG, Daly MJ, Hirschhorn JN, Groop L, Altshuler D: Association testing of variants in the hepatocyte nuclear factor 4 $\alpha$  gene with risk of type 2 diabetes in 7,883 people. *Diabetes* 54:886–892, 2005
- Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, Nissen M, Ehrnstrom BO, Forsen B, Isomaa B, Snickars B, Taskinen MR: Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. *Diabetes* 45:1585–1593, 1996
- Florez JC, Burt N, de Bakker PIW, Almgren P, Tuomi T, Holmkvist J, Gaudet D, Hudson TJ, Schaffner SF, Daly MJ, Hirschhorn JN, Groop L, Altshuler D: Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. *Diabetes* 53:1360–1368, 2004
- Florez JC, Sjogren M, Burt N, Orho-Melander M, Schayer S, Sun M, Almgren P, Lindblad U, Tuomi T, Gaudet D, Hudson TJ, Daly MJ, Ardlie KG, Hirschhorn JN, Altshuler D, Groop L: Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. *Diabetes* 53:3313–3318, 2004
- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. *Science* 296:2225–2229, 2002
- Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Koster H: Chip-based genotyping by mass spectrometry. *Proc Natl Acad Sci U S A* 96:10016–10020, 1999

21. Purcell S, Cherny SS, Sham PC: Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 19:149–150, 2003
22. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am J Hum Genet* 52:506–516, 1993
23. Boehnke M, Langefeld CD: Genetic association mapping based on discordant sib pairs: the discordant-alleles test. *Am J Hum Genet* 62:950–961, 1998
24. Lohmueller K, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. *Nat Genet* 33:177–182, 2003
25. Reis IM, Hirji KF, Affi AA: Exact and asymptotic tests for homogeneity in several  $2 \times 2$  tables. *Stat Med* 18:893–906, 1999
26. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. *Nat Genet* 29:306–309, 2001
27. Ardlie KG, Lunetta KL, Seielstad M: Testing for population subdivision and association in four case-control studies. *Am J Hum Genet* 71:304–311, 2002
28. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, Smoller JW, Pato CN, Pato MT, Petryshen TL, Kolonel LN, Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler D: Assessing the impact of population stratification on genetic association studies. *Nat Genet* 36:388–393, 2004